Last reviewed · How we verify
switch twice-daily insulin
Insulin replacement therapy that provides basal and bolus glucose control through twice-daily subcutaneous injections to manage blood glucose in diabetes.
Insulin replacement therapy that provides basal and bolus glucose control through twice-daily subcutaneous injections to manage blood glucose in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | switch twice-daily insulin |
|---|---|
| Also known as | NovoMix® 30 Penfill®, lantus®, levemir®, NovoRapid® |
| Sponsor | Mackay Memorial Hospital |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Twice-daily insulin regimens typically combine intermediate-acting or long-acting insulin (basal) with rapid-acting insulin (bolus) to mimic physiologic insulin secretion. This approach addresses both fasting glucose levels and postprandial glucose excursions in patients with type 1 or type 2 diabetes who require insulin therapy.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus requiring insulin therapy
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes (PHASE3)
- COMMETS- Combination MCI Metabolic Syndrome (PHASE2)
- A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus (PHASE3)
- Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (PHASE4)
- Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus (PHASE4)
- Insulin Secretion and Advagraf (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- switch twice-daily insulin CI brief — competitive landscape report
- switch twice-daily insulin updates RSS · CI watch RSS
- Mackay Memorial Hospital portfolio CI